Daniel van den Bergh


Daniel is a Director at Kaiser Permanente Ventures. He joined the firm in 2017 and covers all aspects of the investment lifecycle including deal sourcing, due diligence, deal execution, and portfolio company support. Daniel currently serves as Board Director with Nuvolo, Protenus, and Validic. He is a Board Observer with Ordr and Talix. He has also been involved in KPV’s investments in Collective Medical, NextHealth, Vesta Healthcare, Ginger.io, Health Catalyst, and Leiter’s.


Daniel brings expertise in healthcare startup operations, venture capital, and investment banking. Prior to joining us, he was Director of Strategy & Operations at Lumiata, a clinical analytics platform that predicts disease risk. He previously worked at Safeguard Scientifics, a healthcare and technology venture capital firm, focusing on investment opportunities in healthcare IT, specialty pharmaceuticals, diagnostics, and medical devices. Daniel started his career in healthcare investment banking where he worked on cross-border acquisitions in the US, Europe, and the Middle East at Citigroup and EC Mergers & Acquisitions.


Daniel holds an MBA in Health Care Management from The Wharton School and a BS in Biological Engineering from Cornell University.

Miles cycled per year
Countries visited
Languages spoken without an accent